223 related articles for article (PubMed ID: 1711133)
1. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
[TBL] [Abstract][Full Text] [Related]
2. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
Akimoto S; Akakura K; Shimazaki J
Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of tumor markers in prostatic cancer].
Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
[TBL] [Abstract][Full Text] [Related]
4. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
Fuse H; Umeda K; Mizuno I; Katayama T
Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer].
Demura T; Watarai Y; Togashi M; Oohashi N; Chikaraishi T; Hirano T
Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1046-53. PubMed ID: 7688442
[TBL] [Abstract][Full Text] [Related]
6. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
[TBL] [Abstract][Full Text] [Related]
7. Serum gamma-seminoprotein determination in prostatic cancer.
Shimazaki J; Akimoto S; Akakura K; Yoshiki T; Yoshida O; Okada K; Matsuoka K; Noda S; Eto K
Hinyokika Kiyo; 1991 Apr; 37(4):341-7. PubMed ID: 1716404
[TBL] [Abstract][Full Text] [Related]
8. [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].
Shinoda I
Nihon Gan Chiryo Gakkai Shi; 1990 Nov; 25(11):2627-39. PubMed ID: 1703555
[TBL] [Abstract][Full Text] [Related]
9. Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase.
Arai Y; Yoshiki T; Okada K; Yoshida O
Urol Int; 1989; 44(3):135-40. PubMed ID: 2473564
[TBL] [Abstract][Full Text] [Related]
10. [Prostate specific antigen in serum of the patients with prostatic cancer].
Akimoto S; Akakura K; Fuse H; Shimazaki J
Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678
[TBL] [Abstract][Full Text] [Related]
11. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of tumor markers in prostatic carcinoma--comparative study of prostatic acid phosphatase, prostate specific antigen and gamma-seminoprotein].
Yoshiki T; Okada K; Oishi K; Yoshida O
Hinyokika Kiyo; 1987 Dec; 33(12):2044-9. PubMed ID: 2452559
[TBL] [Abstract][Full Text] [Related]
14. Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate.
Siddall JK; Shetty SD; Cooper EH
Clin Chem; 1986 Nov; 32(11):2040-3. PubMed ID: 2430732
[TBL] [Abstract][Full Text] [Related]
15. [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].
Akimoto S; Akakura K; Masai M; Isaka S; Shimazaki J
Hinyokika Kiyo; 1990 Jul; 36(7):783-91. PubMed ID: 1700588
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm)].
Tsukamoto T; Kumamoto Y; Yamazaki K; Umehara T; Miyao N; Ohmura K; Iwazawa M
Hinyokika Kiyo; 1988 Jun; 34(6):987-95. PubMed ID: 2464917
[TBL] [Abstract][Full Text] [Related]
17. [The significance of serum gamma-seminoprotein in prostatic cancer].
Ishikawa S; Tozuka K; Ishiyama S; Goto K; Ohba S; Tokue A; Yonese Y; Kamachi S; Sakurabayashi I; Kawai T
Hinyokika Kiyo; 1985 Jun; 31(6):961-7. PubMed ID: 2414979
[TBL] [Abstract][Full Text] [Related]
18. Diurnal rhythm of serum gamma-seminoprotein in patients with untreated prostate cancer: comparison of the original and revised assay kits.
Akimoto S; Akakura K; Ohki T; Shimazaki J
Int J Urol; 1994 Sep; 1(3):263-7. PubMed ID: 7542157
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA].
Gotoh A; Mizuno Y; Takenaka A; Gohji K; Ogawa T; Arakawa S; Kamidono S; Harada K; Nagata H; Hirooka K
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):467-72. PubMed ID: 1712873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
